Coronavirus / COVID

Investigators sought to summarize evidence about the benefits and harms of hydroxychloroquine and chloroquine as treatments or prophylaxis of COVID-19.

Kelly Cawcutt, MD, MS, shares her thoughts on COVID's impact on health care, as well as why it's so important for clinicians to take breaks.

A new report outlines the proven steps needed to implement a national strategy for SARS-CoV-2 screening.

Early links between heart disease and diabetes and coronavirus severity caused some to fear that the 2 classes of medication might worsen outcomes during the pandemic. A systematic review finds little evidence to back those fears.

A brief on our top stories from May 28, 2020.

Collected specimens can be tested with the Quest Diagnostics SARS-CoV-2 RT-PCR test to have received EUA from the FDA earlier in March.

Debbie Goff, PharmD, describes how antimicrobial stewardship work has continued during the COVID-19 pandemic.

Experts argue that though public officials may liken coronavirus to "just another flu," the true numbers show a stark difference.

Less ACE2 in nasal epithelium in children could present barrier to SARS-CoV-2 and explain the lower observed rate of pediatric infections.

An assessment of severe coronavirus patients administered either five-day or 10-day remdesivir treatment shows benefit is fairly similar, regardless of duration.

A new paper analyzed cancer types to determine which types of cancer put a patient at highest risk of contracting coronavirus.

A daily news update on our COVID-19 coverage.

Helen W. Boucher, MD, FACP, FIDSA, discusses the need for a transparent distribution process for remdesivir, plus COVID disparities, secondary infections, and what “the new normal” of health care looks like.

Clinicians should be wary of risk for depression, anxiety, fatigue, PTSD, and, potentially, rare neuropsychiatric syndromes, in post-coronavirus patients.

While not without its challenges, converting a pediatric intensive care unit to care for adult novel coronavirus patients was the right decision for the Mass General Hospital for Children.

Executive members of coronavirus therapy candidate global assessment came to decision after new data showed the therapy was linked to increased mortality and cardiovascular event risk.

Preliminary results were highly anticipated, given Anthony Fauci, MD, made optimistic statements about the drug in late April.

An analysis by health officials in the UK shows patients in the community (as opposed to the hospital) who were tested for coronavirus had the highest rate of positive results.

A brief summary of the latest infectious disease news.

In his June Editor-in-Chief letter, Dr. Jason Gallagher explores the influence of preprints amid the COVID-19 pandemic.

Vickie Mays, PhD, uses her training in clinical psychology to provide insight on the long-term cognitive impact of the coronavirus pandemic and outbreak response.

The financial support will ensure AstraZeneca will develop at least 400 million doses, with plans to begin distribution in September.

Saskia v. Popescu, PhD, MPH, MA, CIC, discusses vaccine development, fighting COVID misinformation, and lessons learned from the pandemic.

Adding thromboelastogram to D-dimer measure could enable early ID of patients who require aggressive anticoagulation for severe COVID-19.

There may be more fatalities linked to COVID-19 in Los Angeles County than previously thought.